Chemotherapy of Testis Cancer

Area of Science:

• Oncology
• Medical Chemotherapy
• Clinical Trials

Background:

• Metastatic testis cancer historically had rare durable complete remissions before cisplatin-based chemotherapy.
• The introduction of cisplatin, vinblastine, and bleomycin (PVB) in 1977 demonstrated high response rates and manageable toxicity.
• The bleomycin, etoposide, and cisplatin (BEP) regimen is now standard for good- and poor-risk metastatic testicular cancer.

Purpose of the Study:

• To review prospective, randomized clinical trials that have advanced the treatment of metastatic testis cancer.
• To summarize current standard therapies and emerging salvage strategies for testicular cancer.
• To identify areas for future research to improve patient survival.

Main Methods:

• Review of prospective, randomized clinical trials in metastatic testis cancer treatment.
• Analysis of treatment outcomes, response rates, and toxicities.
• Categorization of patients based on risk stratification.

Main Results:

• Risk categories for metastatic testis cancer have been established.
• Bleomycin, etoposide, and cisplatin (BEP) therapy remains the standard for both good- and poor-risk disease.
• High-dose chemotherapy with stem cell rescue is under investigation for chemotherapy-resistant cases.

Conclusions:

• Current treatments for metastatic testicular cancer offer a promising outlook.
• Approximately one-third of "poor-risk" patients still do not achieve remission.
• Further trials investigating novel agents and therapeutic approaches are essential to enhance patient survival.